His weekly medicine roundup lists Lilly's triple agonist results next to the optogenetics Nobel and an ARPA-H plan to speed drug development.
Recap by typeshit. Post by Samuel Hume on X.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Presented at EASD, the analysis put Foundayo 17.2 mg ahead by 1.5% in weight loss and 0.3% in A1C at 52 weeks, though no head-to-head trial was run.
The OCTANE analysis of 194 Ro telehealth patients was presented at EASD 2026. It had no comparison group, and patients who stopped treatment were left out.
Loading…